多發性骨髓瘤市場 - KOL的考察

本報告提供多發性骨髓瘤市場相關調查分析，對已上市的治療方法和開發平台有的治療方法的KOL的考察。

目錄

摘要整理

現在與未來的治療流程

調查目的

單株抗體(mAb)

• 已通過核準的醫藥品
  • Darzalex（daratumumab；楊森）
  • Sarclisa（isatuximab；賽諾菲）
• 正在研究藥物
  • Modakafusp alfa（TAK-573；武田）

免疫調節藥物 (IMiD)

• 正在研究藥物
  • 伊貝多胺（CC-220；BMS）和美齊格多胺（CC-92480；BMS）

細胞凋亡刺激劑

• 正在研究藥物
  • Venetoclax（Venclexta/Venclyxto；艾伯維/基因泰克）

CAR T 細胞療法

• 核准的治療方法
  • Abecma（idecabtagene vicleucel；BMS/2seventy bio）
  • Carvykti（ciltacabtagene autoleucel；Janssen/Legend Biotech）
• 管道療法
  • 新型 CAR T 細胞療法（Gilead [Kite]/Arcellx 的 CART-ddBCMA；BMS 的 BMS-986393）

雙特異性抗體

• 核准的藥品
  • Tecvayli（teclistamab；楊森）
• 正在研究藥物
  • 針對 BMCA 的雙特異性抗體（輝瑞的 elranatamab；再??生元的 linvoseltamab；艾伯維的 ABBV-383）
  • 具有新標靶的雙特異性抗體（楊森的 talquetamab；羅氏的 cevostamab）

未來治療趨勢

• 重要考慮因素摘要

附錄

KOL突發新聞

In which frontline settings is Janssen's widely-used anti-CD38 mAb Darzalex expanding and what factors could increase the prospects of Sanofi's competitor Sarclisa? CAR-T cell therapies such as Janssen's Carvykti may be achieving unprecedented response rates but are hampered by concerns about durability and access. How might readily available bispecific antibody Tecvayli capitalise? KOLs critically assess the prospects of launched and pipeline therapies.

In addition to the full report, licensed users can access the following KOL Bulletins via the Attachments area.

• 31 Aug 2023 KOL Bulletin -- Leading MM specialist discusses outlook for new bispecifics from J&J, Pfizer

Table of Contents

Executive summary

Current and future treatment algorithm

Research objectives

Monoclonal antibodies (mAbs)

• Approved drugs
  • Darzalex (daratumumab; Janssen)
  • Sarclisa (isatuximab; Sanofi)
• Pipeline drugs
  • Modakafusp alfa (TAK-573; Takeda)

Immunomodulatory drugs (IMiDs)

• Pipeline drugs
  • Iberdomide (CC-220; BMS) and mezigdomide (CC-92480; BMS)

Apoptosis stimulants

• Pipeline drugs
  • Venetoclax (Venclexta/Venclyxto; AbbVie/Genentech)

CAR T-cell therapies

• Approved therapies
  • Abecma (idecabtagene vicleucel; BMS/2seventy bio)
  • Carvykti (ciltacabtagene autoleucel; Janssen/Legend Biotech)
• Pipeline therapies
  • Novel CAR T-cell therapies (Gilead [Kite]/Arcellx's CART-ddBCMA; BMS' BMS-986393)

Bispecific antibodies

• Approved drugs
  • Tecvayli (teclistamab; Janssen)
• Pipeline drugs
  • BMCA-targeting bispecific antibodies (Pfizer's elranatamab; Regeneron's linvoseltamab; AbbVie's ABBV-383)
  • Bispecific antibodies with novel targets (Janssen's talquetamab; Roche's cevostamab)

Future treatment trends

• Key insights summary

Appendix

• KOL details
  • KOLs from the USA
  • KOLs from Europe

KOL Bulletins